Abstract:Currently, there is still no effective curative treatment for the development of late-stage liver fibrosis. Here, we have illustrated that TB001, a dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist with higher affinity towards GCGR, could retard the progression of liver fibrosis in various rodent models, with remarkable potency, selectivity, extended half-life and low toxicity. Four types of liver fibrosis animal models which were induced by CCl4, α-naphthyl-isothiocyanate (ANIT), bile duct ligation (BDL) and Schistosoma japonicum were used in our study. We found that TB001 treatment dose-dependently significantly attenuated liver injury and collagen accumulation in these animal models. In addition to decreased levels of extracellular matrix (ECM) accumulation during hepatic injury, activation of hepatic stellate cells was also inhibited via suppression of TGF-β expression as well as downstream Smad signaling pathways particularly in CCl4-and S. japonicum-induced liver fibrosis. Moreover, TB001 attenuated liver fibrosis through blocking downstream activation of pro-inflammatory nuclear factor kappa B/NF-kappa-B inhibitor alpha (NFκB/IKBα) pathways as well as c-Jun N-terminal kinase (JNK)-dependent induction of hepatocyte apoptosis. Furthermore, GLP-1R and/or GCGR knock-down results represented GCGR played an important role in ameliorating CCl4-induced hepatic fibrosis. Therefore, TB001 can be used as a promising therapeutic candidate for the treatment of multiple causes of hepatic fibrosis demonstrated by our extensive pre-clinical evaluation of TB001.

Structure-based design and synthesis of anti-fibrotic compounds derived from para-positioned 3,4,5-trisubstituted benzene

Design, synthesis, and biological evaluation of carbonyl-hydrazine-1-carboxamide derivatives as anti-hepatic fibrosis agents targeting Nur77

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Identification of (E)-1-((1h-indol-3-yl)methylene)-4-substitute-thiosemicarbazones As Potential Anti-Hepatic Fibrosis Agents

Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways

Rational design, synthesis and activities of phenanthrene derivatives against hepatic fibrosis

Design, synthesis and biological evaluation studies of novel anti-fibrosis agents bearing sulfoxide moiety

Synthesis of and anti-fibrotic effect of pyrazole derivative J-1048: Inhibition of ALK5 as a novel approach to liver fibrosis targeting inflammation

Discovery and Development of Benzene Sulfonamide Derivatives As Anti-Hepatic Fibrosis Agents

Design, synthesis and anti-hepatic fibrosis activity of novel diphenyl vitamin D receptor agonists

Design, Synthesis, and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis

Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton

Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis

Design, Synthesis, and Antifibrosis Evaluation of 4-(Benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- Pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-Yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole Derivatives.

The design, synthesis, and biological evaluation of novel YC-1 derivatives as potent anti-hepatic fibrosis agents

Synthesis of Novel 2-(Pyridin-2-yl) Pyrimidine Derivatives and Study of Their Anti-Fibrosis Activity

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

Design, synthesis and anti-fibrosis activity study of N₁-substituted phenylhydroquinolinone derivatives.

Design, synthesis, and evaluation of novel benzoylhydrazone derivatives as Nur77 modulators with potent antitumor activity against hepatocellular carcinoma

Synthesis and Evaluation of Asiatic Acid Derivatives As Anti-Fibrotic Agents: Structure/Activity Studies

Design and Synthesis of Novel Tetrandrine Derivatives As Potential Anti-Tumor Agents Against Human Hepatocellular Carcinoma.